Sickle Cell Disease
Sickle Cell Disease
Advertisement
Andrew MorenoSickle Cell Disease | February 19, 2025
Patients with follow-up of one month or longer saw hemolysis marker improvement and reported no vaso-occlusive crises.
Andrew MorenoSickle Cell Disease | February 18, 2025
In a phase III trial 90% of evaluable patients were free of severe vaso-occlusive crisis for at least 12 consecutive months.
Melissa BadamoSickle Cell Disease | February 13, 2025
Reni-cel led to hemoglobin normalization and increased fetal hemoglobin in patients with sickle cell disease.
Michael DeBaun, MD, MPHSickle Cell Disease | February 18, 2025
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
Andrew MorenoSickle Cell Disease | January 23, 2025
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Andrew MorenoASH 2024 | January 16, 2025
In a study SCT appeared linked to an increased risk of pregnancy-associated VTE, pulmonary embolism, and isolated DVT.
Melissa BadamoSickle Cell Disease | January 16, 2025
Patients receiving mitapivat showed a statistically significant hemoglobin response rate compared with placebo.
Andrew MorenoSickle Cell Disease | January 7, 2025
A review article describes current clinical knowledge of the role of inflammation and the activity of immune cells in SCD.
Nichole TuckerSickle Cell Disease | January 2, 2025
A study's efficacy and safety findings show promise for lovo-cel as a one-time intervention for SCD with history of stroke.
Hamda Khan, MASickle Cell Disease | October 25, 2024
A cohort lifetime study from Hamda Khan, MA, and Jason Hodges, PhD, MA, follows patients from pediatric into adult SCD care.
Theodore Wun, MDSickle Cell Disease | October 22, 2024
Dr. Theodore Wun and Dr. Olubusola Oluwole investigated the causes of rising stroke rates among pediatric and adult patients.
Tamara Diesch-Furlanetto, MDSickle Cell Disease | September 3, 2024
A study has assessed cryogenically preserved ovarian tissue samples from women with SCD for any effects from hydroxyurea.
Kristen Howell, PhD, MpHSickle Cell Disease | July 24, 2024
Kristen Howell, PhD, MPH, has investigated how transfer gaps in SCD care affect patients as they transition to adult care.
Andrew MorenoSickle Cell Disease | July 24, 2024
The REACH trial’s findings suggest a reduced burden upon transfusion resources worldwide is possible.
Melissa BadamoSickle Cell Disease | May 8, 2024
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Patrick DalySickle Cell Disease | May 2, 2024
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Melissa BadamoSickle Cell Disease | May 2, 2024
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
Melissa BadamoSickle Cell Disease | April 26, 2024
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Advertisement